Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NNFA handbook

This article was originally published in The Tan Sheet

Executive Summary

"Do not make claims that your products (or any specific product) is good for the treatment or cure of any disease condition...unless the product bears an appropriate health claim," a new version of the NNFA FDA Handbook for Retailers states. A revised version of the handbook, which includes important information pertaining to the Bioterrorism Act of 2002, was released Jan. 17 by the National Nutritional Foods Association. The publication is designed to help food and health product retailers, including those that sell dietary supplements, determine their rights and obligations during an FDA inspection. For example, FDA is not allowed to inspect a retail location without the presence of an establishment representative, according to the guide. The handbook also makes note of what nutritional information retailers can provide to consumers concerning their products. NNFA members can access the handbook free of charge via the NNFA website; non-members can order the publication through the association's online store...

You may also be interested in...

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts